JPRN-jRCT2080222352已完成3 期
Phase III, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and pharmacokinetics of intravenous MLN0002 (300 mg) infusion in induction and maintenance therapy in Japanese subjects with moderate or severe Crohn's disease
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 157
研究概览
简要总结
Refer to Secondary Outcome Measure
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 15age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •1. Participants aged 15 to 80 years (inclusive) at the time of consent
- •2. Participants with a diagnosis of small-intestinal, large-intestinal, or small-/large-intestinal Crohn's disease established based on the Revised Diagnostic Criteria for Crohn's disease issued by Research Group for Intractable Inflammatory Bowel Disease Designated as Specified Disease by the Ministry of Health, Labor and Welfare of Japan (2012) at least 3 months before the start of administration of study drug
- •3. Participants with baseline Crohn's Disease Activity Index (CDAI) score of 220 to 450 (inclusive) and meeting at least one of the followings
- •- C-reactive protein (CRP)at screening test is above 0.30 mg/dL
- •- Participants with irregular or semicircular ulcers or multiple aphthae (10 or more) observed over an extensive area of the small or large intestine on endoscopy or imaging test within the 4 months before the start of administration of study drugs
- •- Participants with longitudinal ulcers or a cobblestone appearance observed in the small or large intestine on endoscopy or imaging test within 4 months before the start of administration of study drugs
- •4. In case of the participants who meet any of the following criteria; participants with >= 8-year history of extensive or limited colitis, participants aged >= 50 years, or participants with a first-degree family history of colon cancer, those whom the complication of colon cancer or dysplasia was ruled out by total colonoscopy at the start of study drug administration (Or the results from total colonoscopy performed within 1 year before giving consent are available).
- •5. Participants meeting the criteria for treatment failure below with at least one of the following agents received within the previous 5 year period before giving consent.
- •a. Corticosteroids
- •- Resistance
- •- Dependence
- •- Intolerance
- •b. Immunomodulators (azathioprine, 6-mercaptopurine or methotrexate)
- •- Refractory
- •- Intolerance
- •c. Anti-TNF alpha antibodies
- •- Inadequate response
- •- Loss of response
- •- Intolerance
排除标准
- •1. Participants with an evidence of or suspected abdominal abscess
- •2. Participants with a history of subtotal or total colectomy
- •3. Participants who have had a resection of the small intestine in at least 3 locations or have a diagnosis of short bowel syndrome
- •4. Participants with ileostomy, colostomy, or internal fistula, or severe intestinal stenosis
- •5. Participants who started 5-aminosalicylic acid oral drug or probiotics treatment, antimicrobials to treat Crohn's disease, or 30 mg/day or less of oral corticosteroids within 13 days before initiation of study drug administration. If these drugs were used within 14 days before initiation of study drug administration, the dosage must have been changed or their use discontinued within 13 days before the initiation of study drug administration.
- •6. Participants who have received 5-aminosalicylic acid or corticosteroid enemas/suppositories, intravenous corticosteroid injections, or more than 30 mg/day of oral corticosteroids, medications for diarrhea-predominant irritable bowel syndrome, or Chinese herbal medicine for the treatment of Crohn's disease (e.g., Daikenchuto) within 13 days before initiation of study drug administration
- •7. Participants who have received azathioprine, 6-mercaptopurine, or methotrexate within 27 days before initiation of study drug administration. However, this shall not apply to participants who have received these drugs for 83 or more days before initiation of the study drug administration and continued the steady dose administration of the drugs for 27 or more days before initiation of the study drug administration
- •8. Participants who have received cyclosporin, tacrolimus, tofacitinib or any study drugs for treatment of ulcerative colitis within 27 days before initiation of the study drug administration
- •9. Participants who have received adalimumab within 27 days before initiation of study drug administration or any biological drugs other than adalimumab within 55 days before initiation of the study drug administration. Topical administration (such as intraocular implantation for treatment of age-related maculopacy) is allowed
- •10. Participants who have received any live vaccinations within 27 days before initiation of study drug administration
- •11. Participants who have undergone intestinal resection within 27 days before initiation of study drug administration or those anticipated to require intestinal resection during the study
- •12. Participants who have received leukocytapheresis or granulocyte apheresis within 27 days before initiation of the study drug administration
- •13. Participants who have received intravenous hyperalimentation or total enteral nutrition within the 20 days before initiation of the study drug administration. Or participants who are fasted.
- •14. Participants who have received enteral nutrition at > 900 kcal/day or started enteral nutrition at <= 900 kcal/day within the 20 days before initiation of the study drug administration.
- •Participants receiving 900 kcal/day or less of enteral nutrition for at least 21 days before initiation of the study drug administration and whom these dosage was changed or the medications were discontinued within 20 days before initiation of the study drug administration
- •15. Participants with evidence of adenomatous colonic polyps that need to be removed at the start of study drug administration
- •16. Participants with a history or an complication of dysplasia of the small or large intestine
研究者
相似试验
已完成
3 期
Phase 3 study of MLN0002 (300 mg) in treatment of ulcerative colitisJPRN-jRCT2080222353TAKEDA PHARMACEUTICAL COMPANY LTD.292
终止
3 期
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related ToxicityBreast CancerNCT05128773Sanofi3
进行中（未招募）
3 期
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT04194775CStone Pharmaceuticals534
进行中（未招募）
不适用
PGL4001 Efficacy Assessment in Reduction of symptoms due to uterine Leiomyomata (PEARL IV)nterine myomas are benigne, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumors of the female reproductive tract in the pre-menopausal women and mostly asymptomatic affecting 40% of women between 35 and 55 years. When symptomatic, the main symptoms are heavy uterine bleeding, abdominal pressure, abdominal pain, increased urinary frequency and infertility.MedDRA version: 14.1Level: LLTClassification code 10046801Term: Uterine myomaSystem Organ Class: 100000004864EUCTR2012-000036-26-ITPREGLEM SA437
招募中
3 期
Efficacy and Safety of AJU-C52 in Essential Hypertension PatientsEssential HypertensionNCT06416865AJU Pharm Co., Ltd.190